CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 18 enrolled
Drug / intervention
Bortezomibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00722722
NCT00722722Phase 2Completed
CompareCT.gov

The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

Mayo Clinic·interventional·Posted Jul 28, 2008·Updated May 9, 2016

In Brief

A Phase 2 clinical trial evaluating Bortezomib for Kidney Transplantation. Completed, enrolled 18 participants across 1 site.

Detailed Summary

Patients planning to have kidney transplantation who are sensitized to their donors have high levels of donor specific alloantibodies. High levels of donor specific antibodies put kidney transplant recipients at risk for rejection very early after transplant. This study is trying to determine if the drug bortezomib (Velcade ™) can reduce donor specific alloantibodies to a level that permits kidney transplantation without a high risk for rejection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Transplantation
CountriesUnited States
CollaboratorsMillennium Pharmaceuticals, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 28, 2008
Enrollment StartJun 1, 2008
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 17.9 years ago

Interventions

Bortezomibdrug

Velcade given in four-dose cycles intravenously (through a vein).